Bachem Webinar – CMC Process Development and Risk Mitigation

Bubendorf, Switzerland: – The latest webinar from Bachem, the leading CDMO for peptides and oligonucleotides manufacturing, will focus on Chemistry, Manufacturing and Controls (CMC) process development and risk mitigation in pharmaceutical production.

The one-hour free-to-register webinar ‘CMC Process Development and Risk Mitigation’ will be hosted on the Zoom platform on April 29, 2025, commencing at 1700 hrs CEST (UTC +2).

Tailored CMC approach

The session will discuss the demanding balances of efficiency, quality and compliance required in developing peptide and oligonucleotide APIs. It will detail the comprehensive CMC development concept that Bachem has established to meet the growing demand for high-quality APIs that meet the toughest clinical and regulatory requirements.

The webinar will show how the CMC approach must be tailored for each product, ensuring flexibility while maintaining rigorous standards. This involves a thorough analysis of process-related risks and ensures full alignment with both clinical timelines and regulatory guidelines.

Expert speakers

The webinar will be presented by Bachem Senior Group Leader in Project Management, Dr.  Daniel Kessler, and Business Development Manager Dr. Vera D’Aloisio.

Dr. Kessler heads a group of six Project Managers, focusing on CMC Development of Peptide APIs. Highly qualified in Biology and Medicinal Biochemistry, Daniel worked for six years as Postdoctoral Researcher in Molecular Cell Biology and Tumor Biology before joining Bachem in 2013.

Dr. Vera D’Aloisio supports Bachem’s European clients in developing novel peptide-based therapeutic drugs. Her PhD research at Liverpool John Moores University and the University of Edinburgh, focused on peptide design and development. Vera began her career in the CRO/CDMO industry in 2022 and joined Bachem in August 2024.

Registration for the webinar is free of charge and can be completed online (see Resources).

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

For further information, see https://www.bachem.com

Resources

Click on Bachem Webinar – CMC Process Development and Risk Mitigation for further details and online registration.
Click on Bachems News to see latest News & Events.